An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data

ConclusionIn patients with PsA, tofacitinib had a safety profile similar to that of other systemic therapies in real-world settings, except for the risk of HZ, a known risk of tofacitinib.Trial RegistrationClinicalTrials.gov: NCT01877668; NCT01882439; NCT01976364.

Source: Drug Safety - January 30, 2020 Category: Drugs & Pharmacology Source Type: research